News
-
-
-
-
-
PRESS RELEASE
Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
Edesa Biotech, Inc. (Nasdaq:EDSA) reported financial results for Q1 2024 and detailed progress on clinical developments for its biopharmaceutical assets, including ARDS drug candidate EB05 and dermatitis drug candidate EB01. The company also announced future plans for key industry conferences and engagement with potential commercialization partners -
PRESS RELEASE
Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week
Edesa Biotech, Inc. (Nasdaq:EDSA) will be participating in the 2024 Dermatology Summit on January 7, 2024, and in one-on-one meetings alongside the J.P. Morgan 42nd Annual Healthcare Conference from January 8-11, 2024 in San Fransico, California. Attendees interested in meeting with management can request meetings by contacting Edesa at investors@edesabiotech.com. Edesa Biotech is a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases. The company is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), and has also received regulatory approval to conduct a Phase 2 trial of its EB06 monoclonal antibody as a treatment for vitiligo. Additionally, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD) and is planning a future Phase 2 study of paridiprubart for fibrotic diseases. For more information, contact Gary Koppenjan at (289) 800-9600 or investors@edesabiotech.com. -
PRESS RELEASE
Edesa Biotech Reports Fiscal Year 2023 Results
-
-
-
